Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies. - Wang, Kun; Pan, Chaohsuan; Xu, Fengyan; Tse, Archie N.; Sheng, Yucheng (British Journal of Clinical Pharmacology, 2025)